To study the effects of drug procurement under cap price policy (DPUCP)in Sanming,changes in drug category,price, availability and corporate structure were analyzed using purchasing data of the 7th and 8th centralized...To study the effects of drug procurement under cap price policy (DPUCP)in Sanming,changes in drug category,price, availability and corporate structure were analyzed using purchasing data of the 7th and 8th centralized drug procurement in Fujian Province and the 1st drug procurement under cap price in Sanming,and a field investigation was conducted.(1)The amounts of bid-winning drugs and pharmaceutical makers decreased sharply,leading to optimization of drug category and supplier structure. (2)The procurement could meet clinical demands,though a small percentage of drugs were out of stock.(3)Drug prices fell in general,with 10%decline in domestic drugs with a unit package price over RMB 5yuan,a slight price reduction in imported drugs,and some price increase in cheap domestic drugs with a unit package price under RMB 3yuan.DPUCP policy in Sanming optimized procurement drug category and supplier structure,reduced price,and improved industrial structure.However,problems still existed,such as shortage of some drugs and little price reduction in imported and brand-name drugs.展开更多
To evaluate the long-term effect of Drug Purchasing under Joint Price Caps Policy in Fujian Province on price,prescription volume,medical insurance expense and patient’s burden a total of 59968 reimbursement records,...To evaluate the long-term effect of Drug Purchasing under Joint Price Caps Policy in Fujian Province on price,prescription volume,medical insurance expense and patient’s burden a total of 59968 reimbursement records,during the period of 2012.1-2018.8,were processed into monthly data and analyzed through interrupted time series(ITS)regression models.The ITS analysis showed that after the implementation of the policy,(1)the price of competitive drugs was significantly increased by 128.9%(P<0.01),while the price of non-competitive drugs was significantly decreased by 18.9%(P<0.01).(2)The prescription volume of sample drugs was decreased by 32.3%(P<0.01),and that of competitive drugs was decreased by 45.9%(P<0.01),while that of non-competitive drugs was increased by 19.1%(P<0.01).(3)There was no significant change in the monthly medical insurance expense per capita of sample drugs.(4)There was no significant effect on the overall patient’s burden,while the out-of-pocket payment per capita of competitive drugs was increased by 81.4%(P<0.01).展开更多
文摘To study the effects of drug procurement under cap price policy (DPUCP)in Sanming,changes in drug category,price, availability and corporate structure were analyzed using purchasing data of the 7th and 8th centralized drug procurement in Fujian Province and the 1st drug procurement under cap price in Sanming,and a field investigation was conducted.(1)The amounts of bid-winning drugs and pharmaceutical makers decreased sharply,leading to optimization of drug category and supplier structure. (2)The procurement could meet clinical demands,though a small percentage of drugs were out of stock.(3)Drug prices fell in general,with 10%decline in domestic drugs with a unit package price over RMB 5yuan,a slight price reduction in imported drugs,and some price increase in cheap domestic drugs with a unit package price under RMB 3yuan.DPUCP policy in Sanming optimized procurement drug category and supplier structure,reduced price,and improved industrial structure.However,problems still existed,such as shortage of some drugs and little price reduction in imported and brand-name drugs.
文摘To evaluate the long-term effect of Drug Purchasing under Joint Price Caps Policy in Fujian Province on price,prescription volume,medical insurance expense and patient’s burden a total of 59968 reimbursement records,during the period of 2012.1-2018.8,were processed into monthly data and analyzed through interrupted time series(ITS)regression models.The ITS analysis showed that after the implementation of the policy,(1)the price of competitive drugs was significantly increased by 128.9%(P<0.01),while the price of non-competitive drugs was significantly decreased by 18.9%(P<0.01).(2)The prescription volume of sample drugs was decreased by 32.3%(P<0.01),and that of competitive drugs was decreased by 45.9%(P<0.01),while that of non-competitive drugs was increased by 19.1%(P<0.01).(3)There was no significant change in the monthly medical insurance expense per capita of sample drugs.(4)There was no significant effect on the overall patient’s burden,while the out-of-pocket payment per capita of competitive drugs was increased by 81.4%(P<0.01).
